Cargando…

p150(glued)-Associated Disorders Are Caused by Activation of Intrinsic Apoptotic Pathway

Mutations in p150(glued) cause hereditary motor neuropathy with vocal cord paralysis (HMN7B) and Perry syndrome (PS). Here we show that both overexpression of p150(glued) mutants and knockdown of endogenous p150(glued) induce apoptosis. Overexpression of a p150(glued) plasmid containing either a HMN...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ishikawa, Kei-Ichi, Saiki, Shinji, Furuya, Norihiko, Yamada, Daisuke, Imamichi, Yoko, Li, Yuanzhe, Kawajiri, Sumihiro, Sasaki, Hironori, Koike, Masato, Tsuboi, Yoshio, Hattori, Nobutaka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3983229/ https://www.ncbi.nlm.nih.gov/pubmed/24722468 http://dx.doi.org/10.1371/journal.pone.0094645

Ejemplares similares

Decreased long-chain acylcarnitines from insufficient β-oxidation as potential early diagnostic markers for Parkinson’s disease
por: Saiki, Shinji, et al.
Publicado: (2017)

Plasma metabolite biomarkers for multiple system atrophy and progressive supranuclear palsy
por: Mori, Akio, et al.
Publicado: (2019)

A metabolic profile of polyamines in parkinson disease: A promising biomarker
por: Saiki, Shinji, et al.
Publicado: (2019)

Serum caffeine and metabolites are reliable biomarkers of early Parkinson disease
por: Fujimaki, Motoki, et al.
Publicado: (2018)

PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy
por: Matsuda, Noriyuki, et al.
Publicado: (2010)

Shared Metabolic Profile of Caffeine in Parkinsonian Disorders
por: Takeshige‐Amano, Haruka, et al.
Publicado: (2020)

Low Dose of Clonazepam Is Effective in the Treatment of Painless Legs and Moving Toes Syndrome: A Case Report
por: Kawajiri, Sumihiro, et al.
Publicado: (2015)

A Case of Painless Legs and Moving Toes Syndrome in Parkinson's Disease Responsive to Dopaminergic Therapy
por: Kawajiri, Sumihiro, et al.
Publicado: (2016)

Apoptotic Cleavage of Cytoplasmic Dynein Intermediate Chain and P150(Glued)Stops Dynein-Dependent Membrane Motility
por: Lane, Jon D., et al.
Publicado: (2001)

Occipital lobe seizures and subcortical T2 and T2* hypointensity associated with nonketotic hyperglycemia: a case report
por: Sasaki, Fuyuko, et al.
Publicado: (2016)

Non-invasive diagnostic tool for Parkinson’s disease by sebum RNA profile with machine learning
por: Uehara, Yuya, et al.
Publicado: (2021)

Multi-year whole-blood transcriptome data for the study of onset and progression of Parkinson’s Disease
por: Valentine, Matthew N. Z., et al.
Publicado: (2019)

Identifying Therapeutic Agents for Amelioration of Mitochondrial Clearance Disorder in Neurons of Familial Parkinson Disease
por: Yamaguchi, Akihiro, et al.
Publicado: (2020)

Aurora A contributes to p150(glued) phosphorylation and function during mitosis
por: Romé, Pierre, et al.
Publicado: (2010)

Metabolomic analysis data of MPP(+)-exposed SH-SY5Y cells using CE-TOFMS
por: Amo, Taku, et al.
Publicado: (2020)

Dynactin Subunit p150(Glued) Is a Neuron-Specific Anti-Catastrophe Factor
por: Lazarus, Jacob E., et al.
Publicado: (2013)

Schizophrenia-associated dysbindin modulates axonal mitochondrial movement in cooperation with p150(glued)
por: Suh, Bo Kyoung, et al.
Publicado: (2021)

Systemic Metabolic Alteration Dependent on the Thyroid‐Liver Axis in Early PD
por: Miyamoto, Kengo, et al.
Publicado: (2022)

Randomized double-blind placebo-controlled trial of hydrogen inhalation for Parkinson’s disease: a pilot study
por: Yoritaka, Asako, et al.
Publicado: (2021)

A role for regulated binding of p150(Glued) to microtubule plus ends in organelle transport
por: Vaughan, Patricia S., et al.
Publicado: (2002)

TRAPPC9 Mediates the Interaction between p150(Glued) and COPII Vesicles at the Target Membrane
por: Zong, Min, et al.
Publicado: (2012)

Real‐World Nonmotor Changes in Patients with Parkinson's Disease and Motor Fluctuations: J‐FIRST
por: Watanabe, Hirohisa, et al.
Publicado: (2020)

Collective Expert Perspectives on the Use of Safinamide as Adjunctive Therapy for Parkinson's Disease: Online-Based Delphi Survey
por: Takeda, Atsushi, et al.
Publicado: (2022)

Propagative α-synuclein seeds as serum biomarkers for synucleinopathies
por: Okuzumi, Ayami, et al.
Publicado: (2023)

Mutations in Fis1 disrupt orderly disposal of defective mitochondria
por: Shen, Qinfang, et al.
Publicado: (2014)

Aurora A is involved in central spindle assembly through phosphorylation of Ser 19 in P150Glued
por: Reboutier, David, et al.
Publicado: (2013)

Aurora A is involved in central spindle assembly through phosphorylation of Ser 19 in P150Glued
por: Reboutier, David, et al.
Publicado: (2013)

Zonisamide Administration Improves Fatty Acid β-Oxidation in Parkinson’s Disease
por: Ueno, Shin-Ichi, et al.
Publicado: (2018)

Plasma taurine is an axonal excitability-translatable biomarker for amyotrophic lateral sclerosis
por: Nakazato, Tomoko, et al.
Publicado: (2022)

Molecular genetics of Parkinson’s disease: Contributions and global trends
por: Funayama, Manabu, et al.
Publicado: (2022)

Cytoplasmic dynein binds dynactin through a direct interaction between the intermediate chains and p150Glued
Publicado: (1995)

Phosphorylation of EB1 regulates the recruitment of CLIP-170 and p150(glued) to the plus ends of astral microtubules
por: Ran, Jie, et al.
Publicado: (2016)

Correction: Long-term effects of safinamide adjunct therapy on levodopa-induced dyskinesia in Parkinson’s disease: post-hoc analysis of a Japanese phase III study
por: Hattori, Nobutaka, et al.
Publicado: (2022)

Long-term effects of safinamide adjunct therapy on levodopa-induced dyskinesia in Parkinson’s disease: post-hoc analysis of a Japanese phase III study
por: Hattori, Nobutaka, et al.
Publicado: (2022)

Establishment of an in vitro model for analyzing mitochondrial ultrastructure in PRKN-mutated patient iPSC-derived dopaminergic neurons
por: Yokota, Mutsumi, et al.
Publicado: (2021)

A motor neuron disease–associated mutation in p150(Glued) perturbs dynactin function and induces protein aggregation
por: Levy, Jennifer R., et al.
Publicado: (2006)

Par6α Interacts with the Dynactin Subunit p150(Glued) and Is a Critical Regulator of Centrosomal Protein Recruitment
por: Kodani, Andrew, et al.
Publicado: (2010)

Identification of quantitative trait loci for survival in the mutant dynactin p150Glued mouse model of motor neuron disease
por: Alexander, Guillermo M., et al.
Publicado: (2022)

Identification of Licopyranocoumarin and Glycyrurol from Herbal Medicines as Neuroprotective Compounds for Parkinson's Disease
por: Fujimaki, Takahiro, et al.
Publicado: (2014)

Intrajejunal Infusion of Levodopa/Carbidopa for Advanced Parkinson's Disease: A Systematic Review
por: Tsunemi, Taiji, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ld8dquj0g3n5kqej3867ecmq9c